Market: NMS |
Currency: USD
Address: Dorfstrasse 29
MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
📈 MoonLake Immunotherapeutics Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$20.83
-
Upside/Downside from Analyst Target:
31.36%
-
Broker Call:
14
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
<0%
-
Net Income Growth Range (1Y):
<0%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-02-26
-
EPS Estimate:
-1.01
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for MoonLake Immunotherapeutics
| Date | Reported EPS |
|---|
| 2026-02-26 (estimated upcoming) | - |
| 2025-11-05 | -1.1 |
| 2025-08-05 | -0.87 |
| 2025-05-12 | -0.63 |
| 2025-02-26 | -0.72 |
| 2024-11-07 | -0.56 |
| 2024-08-07 | -0.39 |
| 2024-05-07 | -0.22 |
| 2024-02-29 | -0.12 |
| 2023-11-14 | -0.18 |
| 2023-08-10 | -0.23 |
| 2023-05-11 | -0.23 |
| 2023-03-20 | -0.43 |
| 2022-11-14 | -0.27 |
| 2022-08-12 | -0.34 |
📰 Related News & Research
No related articles found for "moonlake immunotherapeutics".
